FDA Halts Sarepta Shipments - Search News

Order byBest matchMost fresh

News

FDA, Sarepta and Gene therapy

Sarepta under pressure: FDA requests halt of Elevidys shipments

Sarepta Therapeutics (SRPT) stock is in focus after the US Food and Drug Administration (FDA) asked the company to halt shipments of Elevidys, a treatment that has been linked to multiple patient deaths.

Continue reading

· 2d · on MSN

Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths

BioPharma Dive · 1h

FDA asks Sarepta to stop shipping Duchenne gene therapy

11hon MSN

Sarepta extends losses premarket after refusing FDA’s halt request

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

8h

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results